Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America

Ibandronate is a third-generation biphosphonate with recognized antiresorptive efficacy by several international, randomized, double-blind, controlled trials. These studies have not included patients from central america, to the best of our knowledge. Therefore, this open-label, uncontrolled study, was set out to assess the clinical effects of a 6-m treatment course with Ibandronate plus vitamine D and Calcium on bone mineral density and health-related quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoporosis Bone Diseases Bone Diseases, Metabolic Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases

Age range

21 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Catholic University

Buenos Aires, Argentina

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women with a diagnosis of osteoporosis of at-Risk
Have a medical indication to receive Ibandronate+Vitamine D+Calcium

Exclusion criteria

Osteoporosis due to secondary causes

Treatment and study plan

antiresorptive therapy

Drug

Primary outcomes

Bone Mineral Density

Time frame: 6 months
Health-Related Quality of Life

Time frame: 6 months

Secondary outcomes

Adverse Events

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Pontifical Catholic University of Argentina

Other

Registry information

Important dates

Study start: 2013
Primary completion: 2015
Study completion: 2015
First posted: Dec 21, 2015
Registry last updated: Apr 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed